Zuzana Dobiasova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zuzana Dobiasova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Gasperikova
Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
2 shared publications - Juraj Stanik
Department of Paediatrics, Medical Faculty of the Comenius University and National Institute for Children’s Diseases, Slovakia
2 shared publications - Martina Skopkova
Diabgene Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences
2 shared publications Denisa Lobotkova
Department of Paediatrics, Medical Faculty of the Comenius University and National Institute of Children’s Diseases
1 shared publicationEmilia Jancova
Department of Paediatrics, Medical Faculty of the Comenius University and National Institute of Children’s Diseases
1 shared publicationFilip Gregus
Diabgene Laboratory, Institute of Experimental Endocrinology, Biomedical Research Center SAS
1 shared publication
Latest Publications
- Open Access
T1D GRS: a tool for identifying children and adolescents with monogenic diabetes
The aim of this study was to determine the effectiveness of the Type 1 Diabetes Genetic Risk Score (T1D GRS) for the prioritisation of children with newly diagnosed hyperglycaemia for genetic testing of monogenic diabetes. Methods: A cohort of 808 children and adolescents with newly diagnosed hyperglycaemia were collected. All underwent standard clinical follow-up and genetic testing based on the knowledge and means accessible at the time. In this cohort and in 189 control subjects (165 monogenic diabetes patients and 24 healthy individuals), we assessed the T1D GRS2 and 10 SNP GRS scores. We assessed the T1D GRS2 cut-off in our cohort and investigated its utility in addition to negative autoantibody status for the prioritisation of cases for genetic testing for monogenic diabetes. Genetic testing included Sanger sequencing, panel sequencing and MLPA. Results: Applying T1D GRS2 in addition to negative autoantibodies on the newly diagnosed hyperglycaemia cohort substantially decreased the number of unnecessarily tested cases. The pick-up rate was increased three-fold, while the sensitivity of the prioritisation decreased only slightly from 77.8% to 72.2% when compared with autoantibodies alone. The majority of monogenic diabetes cases that escaped this prioritisation for genetic testing had low levels of a single autoantibody and were most probably false positives in the autoantibody testing. The monogenic cases that would not be prioritised using GRS2 and autoantibodies were diagnosed based on clinical phenotype. On the other hand, two monogenic diabetes cases with HNF1B-MODY were not originally diagnosed and were identified only thanks to their low GRS2 value. Conclusions: Using T1D GRS in combination with autoantibody testing is effective in decreasing the number of unnecessarily genetically tested cases. This approach, used in addition to the standard clinical evaluation, can be a valuable tool in the early selection of suitable candidates for molecular testing for monogenic diabetes. Research in Context: What is already known about this subject? Diagnosing monogenic diabetes is important, because gene-tailored treatment is available. In children and adolescents, monogenic diabetes has to be differentiated mostly from type 1 diabetes. Individuals with type 1 diabetes and monogenic diabetes have a different genetic risk for type 1 diabetes. The genetic risk score for type 1 diabetes (T1D GRS) can be computed from disease-associated polymorphisms. What is the key question? What is the utility of T1D GRS as a tool for the prioritisation of cases for genetic testing of monogenic diabetes? What are the new findings? More than half of the children with diabetes with negative autoantibodies (type 2 diabetes excluded) and T1D GRS2 below a cut-off was confirmed genetically as having monogenic diabetes. The combination of T1D GRS2 + negative autoantibodies increased the pick-up rate by genetic testing three-fold compared with negative autoantibodies alone, with only small decrease in sensitivity of the prioritisation. Low T1D GRS can draw interest to cases that would otherwise not be suspected of having monogenic diabetes. How might this affect clinical practice in the foreseeable future? Children and adolescents with confirmed diabetes and normal BMI, negative autoantibodies and low T1D GRS can be prioritised for genetic testing soon after diabetes diagnosis.
Open AccessT1D GRS: a tool for identifying children and adolescents with monogenic diabetes
The aim of this study was to determine the effectiveness of the Type 1 Diabetes Genetic Risk Score (T1D GRS) for the prioritisation of children with newly diagnosed hyperglycaemia for genetic testing of monogenic diabetes. Methods: A cohort of 808 children and adolescents with newly diagnosed hyperglycaemia were collected. All underwent standard clinical follow-up and genetic testing based on the knowledge and means accessible at the time. In this cohort and in 189 control subjects (165 monogenic diabetes patients and 24 healthy individuals), we assessed the T1D GRS2 and 10 SNP GRS scores. We assessed the T1D GRS2 cut-off in our cohort and investigated its utility in addition to negative autoantibody status for the prioritisation of cases for genetic testing for monogenic diabetes. Genetic testing included Sanger sequencing, panel sequencing and MLPA. Results: Applying T1D GRS2 in addition to negative autoantibodies on the newly diagnosed hyperglycaemia cohort substantially decreased the number of unnecessarily tested cases. The pick-up rate was increased three-fold, while the sensitivity of the prioritisation decreased only slightly from 77.8% to 72.2% when compared with autoantibodies alone. The majority of monogenic diabetes cases that escaped this prioritisation for genetic testing had low levels of a single autoantibody and were most probably false positives in the autoantibody testing. The monogenic cases that would not be prioritised using GRS2 and autoantibodies were diagnosed based on clinical phenotype. On the other hand, two monogenic diabetes cases with HNF1B-MODY were not originally diagnosed and were identified only thanks to their low GRS2 value. Conclusions: Using T1D GRS in combination with autoantibody testing is effective in decreasing the number of unnecessarily genetically tested cases. This approach, used in addition to the standard clinical evaluation, can be a valuable tool in the early selection of suitable candidates for molecular testing for monogenic diabetes. Research in Context: What is already known about this subject? Diagnosing monogenic diabetes is important, because gene-tailored treatment is available. In children and adolescents, monogenic diabetes has to be differentiated mostly from type 1 diabetes. Individuals with type 1 diabetes and monogenic diabetes have a different genetic risk for type 1 diabetes. The genetic risk score for type 1 diabetes (T1D GRS) can be computed from disease-associated polymorphisms. What is the key question? What is the utility of T1D GRS as a tool for the prioritisation of cases for genetic testing of monogenic diabetes? What are the new findings? More than half of the children with diabetes with negative autoantibodies (type 2 diabetes excluded) and T1D GRS2 below a cut-off was confirmed genetically as having monogenic diabetes. The combination of T1D GRS2 + negative autoantibodies increased the pick-up rate by genetic testing three-fold compared with negative autoantibodies alone, with only small decrease in sensitivity of the prioritisation. Low T1D GRS can draw interest to cases that would otherwise not be suspected of having monogenic diabetes. How might this affect clinical practice in the foreseeable future? Children and adolescents with confirmed diabetes and normal BMI, negative autoantibodies and low T1D GRS can be prioritised for genetic testing soon after diabetes diagnosis.
- 13 December 2023
- Published by Wiley in Diabetic Medicine
- Vol. 41 (5) , e15265
An alternative approach using hs‐CRP levels and age of onset in diagnostics of HNF1A‐MODY
Aims: The aim is to identify people with HNF1A‐MODY among individuals in diabetic cohort solely based on low hs‐CRP serum level and early diabetes onset.Methods: In 3537 participants, we analyzed the hs‐CRP levels. We analyzed the HNF1A gene in 50 participants (1.4% of the cohort) with type 1 or type 2 diabetes who had hs‐CRP ≤0.25 mg/L and were diagnosed with diabetes mellitus (DM) at the age of 8–40 years. We functionally characterized two identified missense variants.Results: Three participants had a rare variant in the HNF1A gene, two of which we classified as likely pathogenic: c.1369_1384dup (p.Val462Aspfs*92) and c.737T>G (p.Val246Gly), and one as likely benign: c.1573A>T (p.Thr525Ser). Our functional studies revealed that p.Val246Gly decreased HNF1α transactivation activity to ~59% and the DNA binding ability to ~16% of the wild‐type, while p.Thr525Ser variant showed no effect on transactivation activity, DNA binding, nor nuclear localization. Based on the two identified HNF1A‐MODY patients among 3537 people with diabetes, we estimate 0.057% as the minimal HNF1A‐MODY prevalence in Slovakia. A positive predictive value of hs‐CRP ≤0.25 mg/L for finding HNF1A‐MODY individuals was 4.0% (95% CI 0.7%, 13.5%).Conclusions: Hs‐CRP value and age of DM onset could be an alternative approach to current diagnostic criteria with a potential to increase the diagnostic rate of HNF1A‐MODY.
- 13 December 2023
- Published by Wiley in Diabetic Medicine
- Vol. 41 (5) , e15265
An alternative approach using hs‐CRP levels and age of onset in diagnostics of HNF1A‐MODY
Aims: The aim is to identify people with HNF1A‐MODY among individuals in diabetic cohort solely based on low hs‐CRP serum level and early diabetes onset.Methods: In 3537 participants, we analyzed the hs‐CRP levels. We analyzed the HNF1A gene in 50 participants (1.4% of the cohort) with type 1 or type 2 diabetes who had hs‐CRP ≤0.25 mg/L and were diagnosed with diabetes mellitus (DM) at the age of 8–40 years. We functionally characterized two identified missense variants.Results: Three participants had a rare variant in the HNF1A gene, two of which we classified as likely pathogenic: c.1369_1384dup (p.Val462Aspfs*92) and c.737T>G (p.Val246Gly), and one as likely benign: c.1573A>T (p.Thr525Ser). Our functional studies revealed that p.Val246Gly decreased HNF1α transactivation activity to ~59% and the DNA binding ability to ~16% of the wild‐type, while p.Thr525Ser variant showed no effect on transactivation activity, DNA binding, nor nuclear localization. Based on the two identified HNF1A‐MODY patients among 3537 people with diabetes, we estimate 0.057% as the minimal HNF1A‐MODY prevalence in Slovakia. A positive predictive value of hs‐CRP ≤0.25 mg/L for finding HNF1A‐MODY individuals was 4.0% (95% CI 0.7%, 13.5%).Conclusions: Hs‐CRP value and age of DM onset could be an alternative approach to current diagnostic criteria with a potential to increase the diagnostic rate of HNF1A‐MODY.